• 1
    Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004; 88: 6382.
  • 2
    Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab 2000; 26: 2227.
  • 3
    Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation, in a patient receiving long-term total parenteral nutrition. Am J Clin Nutr 1977; 30: 531538.
  • 4
    Cefalu WT, Hu FB. Role of chromium in human health and in diabetes. Diabetes Care 2004; 27: 27412751.
  • 5
    Vincent JB. Recent advances in the nutritional biochemistry of trivalent chromium. Proc Nutr Soc 2004; 63: 4147.
  • 6
    Anderson RA, Cheng N, Bryden NA et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 17861791.
  • 7
    Martin J, Wang ZQ, Zhang XH et al. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 2006; 29: 18261832.
  • 8
    Kleefstra N, Houweling ST, Jansman FG et al. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2006; 29: 521525.
  • 9
    Gunton JE, Cheung NW, Hitchman R et al. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 2005; 28: 712713.
  • 10
    Nakatani Y, Kaneto H, Kawamori D et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005; 280: 847851.
  • 11
    Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005; 54 (Suppl 2):S73S78.
  • 12
    Ozcan U, Cao Q, Yilmaz E et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457461.
  • 13
    Yusta B, Baggio LL, Estall JL et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391406.
  • 14
    Ozcan U, Yilmaz E, Ozcan L et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 11371140.
  • 15
    Yang X, Palanichamy K, Ontko AC et al. A newly synthetic chromium complex—chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 2005; 579: 14581464.
  • 16
    Li SY, Yang X, Ceylan-Isik AF et al. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia 2006; 49: 14341446.
  • 17
    Yang X, Li SY, Dong F, Ren J, Sreejayan N. Insulin-sensitizing and cholesterol-lowering effects of chromium (D-Phenylalanine)3. J Inorg Biochem 2006; 100: 11871193.
  • 18
    Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 2004; 287: E227E232.
  • 19
    Sreejayan N, Lin Y, Hassid A. NO attenuates insulin signaling and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B-mediated mechanism. Arterioscler Thromb Vasc Biol 2002; 22: 10861092.
  • 20
    Sykiotis GP, Papavassiliou AG. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 2001; 15: 18641869.
  • 21
    Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37: 347356.
  • 22
    Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC. Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 2002; 132: 11071114.
  • 23
    Clodfelder BJ, Gullick BM, Lukaski HC, Neggers Y, Vincent JB. Oral administration of the biomimetic [Cr3O(O2CCH2CH3)6(H2O)3]+ increases insulin sensitivity and improves blood plasma variables in healthy and type 2 diabetic rats. J Biol Inorg Chem 2005; 10: 119130.
  • 24
    Kim DS, Kim TW, Park IK, Kang JS, Om AS. Effects of chromium picolinate supplementation on insulin sensitivity, serum lipids, and body weight in dexamethasone-treated rats. Metabolism 2002; 51: 589594.
  • 25
    Pattar GR, Tackett L, Liu P, Elmendorf JS. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions. Mutat Res 2006; 610: 93100.
  • 26
    Urano F, Wang X, Bertolotti A et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000; 287: 664666.
  • 27
    Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 90479054.
  • 28
    Rui L, Fisher TL, Thomas J, White MF. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem 2001; 276: 4036240367.